EHAVE, Inc. Announces Dr. Muneer A. Ali Joined the Company’s Medical Advisory Board
July 01, 2021 at 08:30 am EDT
Share
EHAVE, Inc. continues its ongoing commitment to strengthen and broaden its capabilities as Dr. Muneer A. Ali joined the Company’s Medical Advisory Board. Dr. Ali will collaborate with other members of Ehave’s Medical Advisory Board to assist and advise the Company on human trials for its cognitive and psychedelic opportunities, as well as assist and advise the Company on mental health analytical platforms. Dr. Muneer A. Ali is a clinical psychiatrist who is the Associate Medical Director and a Child, Adolescent and Adult Psychiatrist at Amen Clinics, Inc. in Atlanta, GA.Dr. Ali takes a particular interest in ADHD, anxiety disorders, and substance use disorders. He completed his training in Psychiatry at the State University of New York, completed a Fellowship in Child and Adolescent Psychiatry, and served as Chief Fellow in his final year. Dr. Ali is double Board-certified in Adult and Child/Adolescent Psychiatry through the American Board of Psychiatry and Neurology. Dr. Ali is a diplomate of the American Board of Psychiatry and Neurology in General, Child, and Adolescent Psychiatry and holds STATE MEDICAL LICENSES in Alabama, Florida, Georgia, Kentucky, North Carolina, South Carolina, and Tennessee. Dr. Ali's work has been published in professional journals such as The Neuroscience of Depression: Genetics, Cell Biology, Neurology, Behavior, and Diet, and he has presented at the Talk About Curing Autism Southeast Regional Conference. Dr. Ali has won such prestigious awards as the 2013 American Academy of Child and Adolescent Psychiatry Educational Outreach Program Award and the 2009 TOUCH Award from the College of Osteopathic Medicine at Nova Southeastern University. In addition to his professional accolades, Dr. Ali has taught graduate level courses at the State University of New York at Buffalo.
Ehave, Inc. is a Canada-based company, which is an engaged in the digital therapeutics delivering evidence-based therapeutic interventions to patients. The Companyâs primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. The Companyâs main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make decisions through data insights. The Companyâs Ehave Infinity Portal offers a machine learning and artificial intelligence platform with a growing set of tools and applications developed by the Company and its partners. This enables patients, healthcare providers and payers to address a range of conditions through data-driven involvement with the tools.